Progress, Potential, and Possibilities Podcast

by | Dec 3, 2025 | Uncategorized

Plus Therapeutics’ growing momentum in central nervous system (CNS) oncology was recently spotlighted when President & CEO Marc Hedrick, MD, joined host Ira S. Pastor on the Progress, Potential, and Possibilities podcast. The in-depth discussion provides a clear, forward-looking view of how #PlusTherapeutics (#PSTV) is building a differentiated position in radiotherapeutics for some of the most challenging CNS cancers.

Watch or listen to the full episode here:
https://lnkd.in/gUxrT_Us

A Strategic Look at the Future of Targeted Radiotherapeutics for CNS Cancers

In under an hour, Dr. Hedrick breaks down the scientific rationale, strategic focus, and clinical opportunities driving the Company’s work—especially in the areas of #leptomeningealmetastases (LM) and recurrent #glioblastoma (#GBM). These two indications, long considered among the most difficult in oncology, represent areas where targeted radiopharmaceuticals may offer meaningful benefits.

Key themes from the conversation include:

Why LM and GBM Are Clear-Cut Opportunities for Radiotherapeutics

Dr. Hedrick details how traditional systemic therapies often fail to penetrate the CNS effectively—creating a critical opening for localized, image-guided radiotherapeutics.
LM and recurrent GBM are highlighted as diseases where:

  • Tumor cells are difficult to reach

  • Standard therapies offer limited benefit

  • Precision dosing and CNS-compatible delivery are essential

These insights underscore the compelling scientific and clinical rationale behind Plus Therapeutics’ lead programs.

2. A Focused, Capital-Efficient Pipeline Strategy

The discussion explores how Plus Therapeutics has intentionally structured a high-impact, cost-efficient radiotherapeutics pipeline, with a clear path to value creation.
Dr. Hedrick outlines:

  • A disciplined approach to R&D investment

  • Prioritization of indications with high unmet need and strong scientific fit

  • The importance of regulatory efficiency and platform scalability

This strategy positions the Company to advance meaningful innovation while maintaining operational focus.

Watch the Full Interview

To hear Dr. Hedrick’s full insights and learn more about how Plus Therapeutics and CNSide are shaping the next era of CNS cancer innovation, visit:
https://lnkd.in/gUxrT_Us